You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
While the first task of the centers will be to digitize their workflows to improve efficiency, they also aim to eventually develop new AI-based analytical tools for diagnosing patients.
Used with other clinical evidence, Siemen Healthineer's blood-based test aids clinicians in assessing the fibrosis stage of chronic liver disease.
The new factory will be the company’s first in vitro diagnostic reagent plant in the Asia Pacific region, producing clinical chemistry and immunoassay reagents.
The companies plan to enable at-home testing by integrating Siemens Healthineers' urinalysis reagents into Healthy.io’s smartphone-based urinalysis system.
Some researchers believe that the use of microfluidics in the analysis of exosomes will help clinicians overcome the problem of heterogeneity in cancer cells.
Becton Dickinson got clearance for a platform and test for the rapid identification and determination of antimicrobial susceptibility of gram-negative bacteria.
Siemens' Atellica BRAHMS PCT assay received clearance from the US Food and Drug Administration on July 16, which the company announced in August.
The test uses the same blood draw of a routine health exam and was designed to be unaffected biotin, a vitamin supplement that may skew some lab test results.
Companies said at AACC that as labs grow larger, they see growth in demand for integrated, modular systems that help customers manage complexity and costs.
Siemens Healthineers received FDA clearances for several assays, including separate allowances for tests using hemoglobin A1c, troponin I, and procalcitonin biomarkers.